Andrew Hamer

Company: Cardiol Therapeutics

Job title: Chief Medical Officer

Seminars:

Moving Beyond Symptom Suppression: Targeting NLRP3 Inflammasome for Disease Modification in Cardiac Conditions 3:00 pm

Targeting the NLRP3 Inflammasome shifting towards addressing the root causes of cardiac conditions, moving beyond traditional symptom management approaches Examining the complex interplay between inflammation, fibrosis, and disease progression Exploring the promise in delaying disease recurrences and modifying the underlying pathophysiology of cardiac conditionsRead more

day: Day 1